ARQT Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
129.9M
+23.2%
105.4M
-18.6%
129.5M
+30.5%
99.2M
+21.7%
81.5M
Cost of Revenue
10.9M
+11.8%
9.8M
-16.3%
11.7M
+34.6%
8.7M
+15.9%
7.5M
Gross Profit
118.9M
+24.4%
95.6M
-18.8%
117.8M
+30.1%
90.5M
+22.3%
74.0M
Operating Expenses
102.5M
-2.1%
104.7M
+5.3%
99.4M
+21.2%
82.0M
-7.5%
88.6M
R&D
20.4M
-33.5%
30.6M
+49.8%
20.5M
+4.3%
19.6M
+0.8%
19.5M
SG&A
82.1M
+10.9%
74.1M
-6.2%
79.0M
+26.6%
62.4M
-9.8%
69.2M
Operating Income
16.4M
+280.8%
-9089000
-149.4%
18.4M
+115.7%
8.5M
+158.4%
-14611000
EBITDA
15.9M
+286.1%
-8527000
-159.7%
14.3M
+57.2%
9.1M
+151.7%
-17590000
Net Income
15.0M
+232.9%
-11295000
-164.9%
17.4M
+134.8%
7.4M
+146.6%
-15886000
EPS (Basic)
$0.11
+222.2%
$-0.09
-164.3%
$0.14
+133.3%
$0.06
+146.2%
$-0.13
EPS (Diluted)
$0.11
+222.2%
$-0.09
-164.3%
$0.14
+133.3%
$0.06
+146.2%
$-0.13
Shares (Diluted)
135.9M
+5.1%
129.4M
+5.2%
123.0M
-7.4%
132.9M
+4.6%
127.0M
Arcutis Biotherapeutics (ARQT) โ€” Financials